Drugs targeted against protein kinases

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Current cancer treatments (surgery, radiation, chemotherapy) are limited by severe side effects and efficacy in advanced disease.
• Understanding oncogenes and tumor suppressor genes has revealed cancer's basis in deregulated cellular signaling pathways.
• Protein kinases are crucial in these signaling pathways, making them key therapeutic targets.

Purpose of the Study:

• To summarize novel cancer therapies targeting molecular pathways, including kinase inhibitors and monoclonal antibodies.
• To highlight the shift towards molecularly targeted cancer treatments.
• To discuss the potential for reduced toxicity and increased efficacy of these new agents.

Main Methods:

• Review of existing literature on targeted cancer therapies.
• Summary of key drugs like Gleevec (imatinib) and Herceptin (trastuzumab).
• Discussion of preclinical and clinical trial findings for kinase inhibitors and receptor antibodies.

Main Results:

• Gleevec (imatinib) demonstrated high remission rates and low toxicity in chronic myelogenous leukemia (CML) by inhibiting kinases.
• Herceptin (trastuzumab), a monoclonal antibody, shows excellent antitumor activity in breast cancer, especially in combination therapies.
• Numerous targeted drugs are in advanced clinical trials, indicating a growing pipeline of molecularly-driven cancer treatments.

Conclusions:

• Targeted therapies, including kinase inhibitors and monoclonal antibodies, represent a new era in cancer treatment.
• These novel agents offer the potential for greater specificity, improved cure rates, and reduced side effects.
• Further clinical studies are expected to yield new, less toxic anticancer agents tailored to specific diseases.